神经内分泌肿瘤肝转移:能否根据多期CT特征诊断不同组织学亚型?
本研究回顾性纳入2013年1月至2017年12月经活检证实、至少有一个肝转移灶且接受标准化多期肝脏CT的神经内分泌肿瘤患者,由两名腹部放射科医生在不知临床资料和组织学亚型的情况下共识分析255个肝转移灶的强化模式及肿瘤-主动脉比、肿瘤-肝脏比。结果显示胰腺、胃肠、肺来源NET肝转移在多期CT强化模式和定量比值上差异有统计学意义,这些CT特征可能有助于在原发灶不明时识别原发肿瘤。
要点
- 胰腺NET肝转移多在动脉期高密度、门脉期和肝静脉期等密度(79.2%)。
- 胃肠NET肝转移多在动脉期高密度、门脉期和肝静脉期低密度(46.7%)。
- 肺NET肝转移最常见为三期均低密度(46.8%)。
核心结论
- 胰腺、胃肠和肺来源NET肝转移在多期CT强化模式、肿瘤-主动脉比和肿瘤-肝脏比上差异有统计学意义,这些CT特征可能有助于原发灶不明时识别原发肿瘤。
研究设计与样本
- 回顾性分析2013年1月至2017年12月经活检证实NET、至少一个肝转移灶并接受标准化多期肝脏CT(动脉期、门脉期、肝静脉期)的患者,共分析255个肝转移灶,由两名腹部放射科医生在不知临床资料和组织学亚型的情况下共识阅片。
关键影像表现/征象
- 胰腺NET肝转移多为动脉期高密度、门脉期和肝静脉期等密度(79.2%,n=80)。
- 胃肠NET肝转移多为动脉期高密度、门脉期和肝静脉期低密度(n=28,46.7%)。
- 肺NET肝转移最常见为三期均低密度(n=44,46.8%)。
- 病灶强化均匀者占78%(n=199),胰腺组(n=90,89.1%)显著高于胃肠组(n=28,46.7%)(p<0.001)。
- 胃肠NET肝转移不均匀强化显著高于其他两组(50% vs 3%和2%)。
诊断标准与关键数值
- 按原发肿瘤部位分组:胰腺NET肝转移101个(39.6%)、胃肠NET肝转移60个(23.5%)、肺NET肝转移94个(36.8%)。
- 肿瘤-主动脉比和肿瘤-肝脏比在胰腺、胃肠和肺NET肝转移间差异有统计学意义(p<0.001),基于聚类数据的ROC分析。
- 肝病灶强化模式按原发肿瘤部位差异有统计学意义(p<0.001)。
临床应用与阅片要点
- 阅片时可结合动脉期、门脉期和肝静脉期的强化模式及肿瘤-主动脉比、肿瘤-肝脏比,辅助原发灶不明时推断NET组织学亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess and compare the multiphasic computed tomography (CT) features of neuroendocrine tumor (NET) liver metastases and to investigate the possibility to predict the histologic subtype of the primary tumor.
MATERIALS AND METHODS: Between January 2013 and December 2017 patients with biopsy proven NET with at least one liver metastasis who underwent multiphasic CT were enrolled in this study. All cases were acquired using a standardized multiphasic liver CT protocol, arterial, portal, and hepatic venous phases were obtained. Images were retrospectively analyzed in consensus by two abdominal radiologists blinded to clinical data and histologic subtype. The size, number, and location of lesions were noted. Enhancement patterns of each lesion on arterial, portal, and hepatic venous phases were assessed. For quantitative analysis, CT attenuation of tumors, liver parenchyma, and aorta were measured using a circular region of interest (ROI) on arterial, portal, and hepatic venous phases for reflecting the blood supply of the tumor. Tumor-to-aorta and tumor-to-liver ratio were calculated in all three phases. Differences between subtypes of NET liver metastases were studied using ROC analysis of clustered data.
RESULTS: A total of 255 neuroendocrine tumor liver metastases divided into 101 (39.6%) pancreatic, 60 (23.5%) gastroenteric and 94 (36.8%) lung NET liver metastases were analyzed. Contrast enhancement of lesions was homogeneous in 78% of patients (n = 199), which was significantly more frequent in patients with pancreatic group than in those with gastroenteric origin (n = 90, 89.1% vs. n = 28, 46.7%; p < 0.001). Gastroenteric NET metastases frequently showed heterogeneous enhancement, which was significantly higher than in the other two groups (50% vs. 3% and 2%). With respect to the location of the primary tumor, the difference in enhancement patterns of the liver lesions was statistically significant (p < 0.001). Pancreatic NET metastases were mostly hyperdense on arterial images and isodense on portal and hepatic venous phase images (79.2%, n = 80). Gastroenteric NET metastases were mostly hyperdense on arterial phase images and hypodense on portal and hepatic venous phase images (n = 28, 46.7%). The most frequent pattern for lung NET metastases was hypoattenuation on all three phase images (n = 44, 46.8%). ROC analysis of clustered data revealed statistically significant differences between pancreatic NET liver metastases, gastroenteric NET liver metastases, and lung NET liver metastases in terms of tumor-to-aorta (T-A) ratio and tumor-to-liver (T-L) ratio (p < 0.001).
CONCLUSION: We observed statistically significant differences in multiphasic CT features (enhancement pattern, T-A ratio, and T-L ratio) between histologic subtypes of NET liver metastases. As the difference in histological subtypes of NET liver metastases results in a different prognosis and different management strategy, these CT features might help to identify the primary tumor when it is not known to ensure accurate tumor staging and to provide optimal treatment.
引用
- Gulpinar B, Peker E, Kul M, et al. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features? Abdom Radiol (NY). 2019. PMID: 30863999. doi:10.1007/s00261-019-01963-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。